Benitec Biopharma Inc. (BNTC)
- Previous Close
6.90 - Open
7.00 - Bid 5.02 x 200
- Ask 8.83 x 200
- Day's Range
6.71 - 7.00 - 52 Week Range
1.86 - 9.01 - Volume
19,742 - Avg. Volume
81,625 - Market Cap (intraday)
57.557M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-236.13 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
benitec.comRecent News: BNTC
Performance Overview: BNTC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTC
Valuation Measures
Market Cap
17.89M
Enterprise Value
-2.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
79.17
Price/Book (mrq)
1.16
Enterprise Value/Revenue
-33.82
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.53%
Return on Equity (ttm)
-178.30%
Revenue (ttm)
61k
Net Income Avi to Common (ttm)
-21.81M
Diluted EPS (ttm)
-236.13
Balance Sheet and Cash Flow
Total Cash (mrq)
20.37M
Total Debt/Equity (mrq)
2.73%
Levered Free Cash Flow (ttm)
-9.6M